Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) has shared an announcement.
Hansa Biopharma has successfully raised approximately USD 71 million through a directed share issue of 17 million shares, aimed at Swedish and international institutional investors. The proceeds will support the company’s strategic initiatives, including a potential Biologic License Application filing with the FDA for imlifidase, and enhancing its medical and commercial capabilities in the U.S. This capital raise is a strategic move to strengthen Hansa’s market position and prepare for the potential U.S. launch of imlifidase, reflecting strong investor confidence and expanding its shareholder base.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biotechnology company based in Lund, Sweden, focused on developing innovative treatments for rare immunological conditions. The company is known for its lead product, imlifidase, which is aimed at enabling kidney transplants for highly sensitized patients.
Average Trading Volume: 524,776
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.3B
See more insights into HNSA stock on TipRanks’ Stock Analysis page.